In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrenceBiomarker testing in early-stage lung cancer New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated NSCLCInterim results from the phase I portion of the CHRYSALIS trial evaluating amivantamab, a bispecific antibody that targets EGFR and MET, in combination with lazertinib, a third-generation EGFR TKI, for the treatment of EGFR-mutated NSCLCPhase I data on the HER3-directed antibody–drug conjugate patritumab deruxtecan for NSCLC with progression on an EGFR TKIPresenters:Helena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkMaria E. Arcila, MDPathologistDirector, Diagnostic Molecular Pathology LaboratoryMemorial Sloan Kettering Cancer CenterNew York, New YorkContent supported by an educational grant from Lilly.Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:http://bit.ly/3a3e1Xs

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related